SCHEMBL16205758

SCHEMBL16205758

O=S(=O)(Nc1cccc(CF)c1)c1cccn1-c1ncc(C(F)(F)F)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
PKM P14618 2/20 0.63
MAPT P10636 5/20 0.57
LMNA P02545 2/20 0.52
NPSR1 Q6W5P4 5/20 0.46
MEN1 O00255 6/20 0.44
KMT2A Q03164 6/20 0.44
PPARG P37231 1/20 0.44
NR2E3 Q9Y5X4 1/20 0.44
NCOR2 Q9Y618 1/20 0.44
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 2/20 0.41
XBP1 P17861 1/20 0.41
POLB P06746 1/20 0.41
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7587623 0.92 PKM (0.67) ALDH1A1SMN1; SMN2PKMMAPTLMNA
SCHEMBL7594148 0.89 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2PKMMAPTLMNA
SCHEMBL7593829 0.88 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2PKMMAPTLMNA
SCHEMBL7594465 0.87 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2PKMMAPTLMNA
SCHEMBL16205810 0.86 PKM (0.60) ALDH1A1SMN1; SMN2PKMMAPTLMNA
SCHEMBL7587369 0.84 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2PKMMAPTLMNA
SCHEMBL7593840 0.84 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2PKMMAPTLMNA
SCHEMBL7590282 0.84 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2PKMMAPTLMNA
SCHEMBL7593843 0.84 PKM (0.59) ALDH1A1SMN1; SMN2PKMMAPTLMNA
SCHEMBL16205811 0.83 PKM (0.58) ALDH1A1SMN1; SMN2PKMMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9657004-B2 Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use AGIOS PHARMACEUTICALS, INC (US) 2017-05-23 US disclosed
US-20140323729-A1 PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323729-A1 PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE PDK2, PDK1, PDK3 ALDH1A1 1387/4885SMN1; SMN2 4384/4885PKM 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.